Abstract
Long-term comparative trials among newer antiepileptic drugs are lacking; therefore decision models are needed to guide treatment decisions. The goal of this study was to develop an economic model of newly diagnosed epilepsy in the UK and to provide the first assessment of topiramate. A Markov model was developed combining data from clinical trials, cost-of illness, mortality, and utility studies. Expected costs and utilities associated with treatment strategies (first- and second-line treatments) were compared to find the cost-effectiveness frontier. First- and second-line monotherapy with topiramate or carbamazepine in partial seizures was less costly and more effective than other scenarios. In generalised seizures first-line topiramate was cost-effective with valproate or lamotrigine as second-line treatments depending on the set of utilities used. Models provide a relevant framework within which costs and health gains of antiepileptic drugs treatment options can be studied. Our findings are further evidence of the promising role of topiramate for patients with newly diagnosed epilepsy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anonymous (2002) Health technology appraisal scope document. Newer drugs for adults with epilepsy. National Institute for Clinical Excellence–
Wallace H, Shorvon S, Tallis R (1998) Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2:052:922 and age-specific fertility rates of women with epilepsy. Lancet 352:1970–1973
Shorvon S (1999) Services for patients with epilepsy. Report of a Clinical Standards Advisory Group committee chaired by A. Kitson. Stationary Office: London
Hanna NJ, Black M, Sander JW, Smithson WH, Appleton R, Brown S, Fish DR (2002) The National Sentinel Clinical audit of epilepsy-related death: epilepsy-death in the shadows. Stationary Office: London
Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman B (2000) How well can epilepsy syndromes be identified at diagnosis? A reassessment 2 years after initial diagnosis. Epilepsia 41:1269–1275
Manford M, Hart YM, Sander JW, Shorvon SD (1992) The National General Practice Study of Epilepsy. The syndromic classification of the International League Against Epilepsy applied to epilepsy in a general population. Arch Neurol 49:801–808
Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE (2000) An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 41 [Suppl 1]:S3–S9
North West Clinical Neuroscience Partnership (NHS) (2001) The management of adults with epilepsy. A North West Clinical Framework
Selai C, Trimble M, Kaiser S, Price M (2002) New anti-epileptic drugs: clinical outcomes and utility scores. Poster P330 at 5th European Congress on Epileptology, 6–10 October, Madrid
Craig BA, Sendi PP (2002) Estimation of the transition matrix of discrete-time Markov chain. Health Econ 11:33–42
Privitera MD, Brodie MJ, Mattson RH, Chadwick D, Neto W, Wang S, for the EPMN 105 Study Group (2003) Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 107:165–175
Jacoby A, Buck D, Baker G, McNamee P, Graham-Jones S, Chadwick D (1998) Uptake and costs of care for epilepsy: findings from a UK regional study. Epilepsia 39:776–786
Netten A, Rees T, Harrison G (eds), Personal Social Services Research Unit (2001) Unit costs of health and social care 2001. University of Kent at Canterbury: Canterbury
Begley CE, Annegers JF, Lairson DR, Reunolds TF, Hauser WA (1994) Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 35:1230–1243
Yuen P (ed) (2001) OHE compendium of health statistics, 13th edn. Office of Health Economics: London
Lhatoo SD, Johnson AL, Goodridge DM, MacDonald BK, Sander JWAS, Shrovon SD (2001) Mortality in epilepsy in the first 11 to 14 years after diagnoses: a multivariate analysis of a long-term, prospective, population-based cohort. Ann Neurol 49:336–344
Nilsson L, Farahmand BY, Persson P-G, Thiblin I, Tomson T (1999) Risk factors for sudden unexpected death in epilepsy: a case-control study. Lancet 353:888–893
Messenheimer J, Mullens EL, Giorgi L, Young F (1998) Safety review of adult clinical trial experience with lamotrigine. Drug Saf 18:281–296
Hebert AA, Ralston JP (2001) Cutaneous reactions to anticonvulsant medications. J Clin Psychiatry 62 [Suppl 14]:22–26
Rosenfeld WE (1997) Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther 19:1294–1308
Fenwick E, Claxton K, Sculpher M (2001) Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 10:779–787
Towse A, Pritchard C, Devlin N (eds) (2002) Cost-effectiveness thresholds—economic and ethical issues. King's Fund and Office of Health Economics
Weinstein MC (1990) Principles of cost-effective resource allocation in health care organisations. Int J Technol Assess Health Care 6:93–105
Brodie MJ, Richens A, Yuen AWC, for the UK Lamotrigine/Carbamazepine Monotherapy Trial Group (1995) Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 345:476–479
Anonymous (2001) British national formulary 42. British Medical Association and the Royal Pharmaceutical Society of Great Britain
OMNILABS (UK) Limited (2000) Directory and price list
Chartered Institute of Public Finance and Accountancy (2000) The health service financial database and comparative tool, 2000. Institute of Public Finance Limited: Croydon
Department of Health (2001) The new NHS-2001 reference costs.http://www.doh.gov.uk/nhsexec/refcosts.htm
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Remák, E., Hutton, J., Price, M. et al. A Markov model of treatment of newly diagnosed epilepsy in the UK. HEPAC 4, 271–278 (2003). https://doi.org/10.1007/s10198-003-0176-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10198-003-0176-3